Tegomil fumarate
 | |
| Clinical data | |
|---|---|
| Trade names | Riulvy |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C18H26O11 |
| Molar mass | 418.395 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tegomil fumarate sold under the brand name Riulvy, is a medication used for the treatment of relapsing remitting multiple sclerosis.[1] It is taken by mouth.[1]
The mechanism of action of tegomil fumarate is not fully understood but it is thought to act via its main active metabolite monomethyl fumarate.[1] This metabolite activates the NRF2 transcriptional pathway, which reduces inflammation and modulates the activity of immune cells, thereby protecting the cells of the central nervous system from damage.[1]
Tegomil fumarate was authorized for medical use in the European Union in July 2025.[2]
Medical uses
[edit | edit source]Tegomil fumarate is indicated for the treatment of people aged thirteen years of age and older with relapsing remitting multiple sclerosis.[1]
Society and culture
[edit | edit source]Legal status
[edit | edit source]In May 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Riulvy, intended for the treatment of adults and children from 13 years of age with relapsing remitting multiple sclerosis.[1] The applicant for this medicinal product is Neuraxpharm Pharmaceuticals, S.L.[1] Riulvy is a hybrid medicine of Tecfidera, which has been authorized in the EU since January 2014.[1] Riulvy contains a different active substance but acts via the same active metabolite as Tecfidera, monomethyl fumarate.[1] Tegomil fumarate was authorized for medical use in the European Union in July 2025.[1][2]
Names
[edit | edit source]Tegomil fumarate is the international nonproprietary name.[3]
References
[edit | edit source]- ^ a b c d e f g h i j k Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value). Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
Lua error in mw.title.lua at line 392: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal'). Lua error in Module:Authority_control at line 153: attempt to index field 'wikibase' (a nil value).
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |